Michel Janssens
Overview
Explore the profile of Michel Janssens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marchant A, Adali S, Alsdurf H, Bol V, Capelle X, De Schrevel N, et al.
J Infect Dis
. 2024 Jun;
230(6):e1274-e1286.
PMID: 38865084
Background: Determinants of maternal-fetal cytomegalovirus (CMV) transmission and factors influencing the severity of congenital CMV (cCMV) infection are not well understood. Methods: We conducted a descriptive, multicenter study in pregnant...
2.
Salaun B, De Smedt J, Vernhes C, Moureau A, Oner D, Bastian A, et al.
Front Immunol
. 2023 Nov;
14:1260146.
PMID: 37936699
Introduction: The immune mechanisms supporting partial protection from reinfection and disease by the respiratory syncytial virus (RSV) have not been fully characterized. In older adults, symptoms are typically mild but...
3.
Waerlop G, Leroux-Roels G, Pagnon A, Begue S, Salaun B, Janssens M, et al.
J Immunol Methods
. 2023 Nov;
523:113584.
PMID: 37918618
The magnitude and quality of cell-mediated immune responses elicited by natural infection or vaccination are commonly measured by Interferon-ɣ (IFN-ɣ) Enzyme-Linked ImmunoSpot (ELISpot) and Intracellular Cytokine Staining (ICS). To date,...
4.
Begue S, Waerlop G, Salaun B, Janssens M, Bellamy D, Cox R, et al.
Front Immunol
. 2022 Nov;
13:982887.
PMID: 36341380
Despite the knowledge that cell-mediated immunity (CMI) contributes to the reduction of severe influenza infection, transmission, and disease outcome, the correlates of protection for cell-mediated immunity remain still unclear. Therefore,...
5.
Galgani I, Annaratone M, Casula D, Di Maro G, Janssens M, Tasciotti A, et al.
Respir Res
. 2022 May;
23(1):114.
PMID: 35509077
Background: Non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections are frequently associated with exacerbations of chronic obstructive pulmonary disease (COPD). Results were reported with a two-dose (0-2 months) schedule...
6.
Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, et al.
NPJ Vaccines
. 2021 May;
6(1):78.
PMID: 34021167
Differences in innate immune 'imprinting' between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses. We compared antibody avidity maturation, antibody/memory B cell/CD4 T cell response...
7.
Moris P, Bellanger A, Ofori-Anyinam O, Jongert E, Yarzabal Rodriguez J, Janssens M
J Immunol Methods
. 2021 Jan;
492:112940.
PMID: 33493551
Vaccinology is confronted with diseases for which the control of T-cell responses by the vaccine is essential. Among the assays that have been designed to assess T-cell responses, intracellular cytokine...
8.
Van Der Meeren O, Jongert E, Seaton K, Koutsoukos M, Aerssens A, Brackett C, et al.
Vaccine
. 2020 Jan;
38(7):1678-1689.
PMID: 31932137
Background: Vaccines eliciting protective and persistent immune responses against multiple human immunodeficiency virus type 1 (HIV-1) clades are needed. This study evaluated the persistence of immune responses induced by an...
9.
Cicconi P, Jones C, Sarkar E, Silva-Reyes L, Klenerman P, de Lara C, et al.
Clin Infect Dis
. 2019 Jul;
70(10):2073-2081.
PMID: 31340042
Background: Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mortality. This Phase I, randomized, observer-blind, placebo- and active-controlled study evaluated an investigational vaccine against RSV...
10.
Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, et al.
J Infect Dis
. 2019 Feb;
219(11):1799-1803.
PMID: 30715452
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following...